Abbott Obtains Exclusive Distribution Rights for OraQuick(R) ADVANCE(TM) Rapid HIV-1/2 Test

Abbott and OraSure Technologies have announced an agreement for the distribution of OraSure Technologies' OraQuick(R) ADVANCE(TM) rapid antibody test for the detection of antibodies to the Human Immunodeficiency Virus Type 1 (HIV-1) and Type 2 (HIV-2).

Under the terms of the distribution agreement, Abbott was appointed as exclusive distributor of the OraQuick(R) ADVANCE(TM) HIV-1/2 test for hospitals and as a non-exclusive distributor to physician offices in the United States.

Providing results in as little as 20 minutes, OraQuick(R) ADVANCE(TM) is the only rapid, point-of-care test for the detection of antibodies to both HIV-1 and HIV-2 approved by the U.S. Food and Drug Administration (FDA) for use on oral fluid, finger stick or venipuncture whole blood, and plasma specimens. The test is also CLIA waived for all specimen types except plasma.